- Home
- KORE vs OTLK Comparison
KORE vs OTLK Comparison
Compare KORE & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KORE
- OTLK
- Stock Information
- Founded
- KORE 2003
- OTLK 2010
- Country
- KORE United States
- OTLK United States
- Employees
- KORE N/A
- OTLK N/A
- Industry
- KORE Telecommunications Equipment
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KORE Consumer Discretionary
- OTLK Health Care
- Exchange
- KORE Nasdaq
- OTLK Nasdaq
- Market Cap
- KORE 45.0M
- OTLK 42.8M
- IPO Year
- KORE N/A
- OTLK 2016
- Fundamental
- Price
- KORE $3.55
- OTLK $1.28
- Analyst Decision
- KORE Hold
- OTLK Buy
- Analyst Count
- KORE 2
- OTLK 5
- Target Price
- KORE $2.75
- OTLK $5.25
- AVG Volume (30 Days)
- KORE 31.3K
- OTLK 1.8M
- Earning Date
- KORE 11-12-2025
- OTLK 08-14-2025
- Dividend Yield
- KORE N/A
- OTLK N/A
- EPS Growth
- KORE N/A
- OTLK N/A
- EPS
- KORE N/A
- OTLK N/A
- Revenue
- KORE $285,636,000.00
- OTLK $1,505,322.00
- Revenue This Year
- KORE $4.46
- OTLK N/A
- Revenue Next Year
- KORE $5.94
- OTLK $342.80
- P/E Ratio
- KORE N/A
- OTLK N/A
- Revenue Growth
- KORE 0.24
- OTLK N/A
- 52 Week Low
- KORE $1.10
- OTLK $0.79
- 52 Week High
- KORE $4.88
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- KORE 66.21
- OTLK 49.12
- Support Level
- KORE $2.99
- OTLK $1.28
- Resistance Level
- KORE $3.83
- OTLK $1.48
- Average True Range (ATR)
- KORE 0.22
- OTLK 0.11
- MACD
- KORE 0.05
- OTLK 0.00
- Stochastic Oscillator
- KORE 70.68
- OTLK 27.78
About KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.